| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
|
Cancer
|
2010
|
2.74
|
|
2
|
Pancreatic cancer and thromboembolic disease.
|
Lancet Oncol
|
2004
|
2.10
|
|
3
|
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.
|
J Clin Oncol
|
2007
|
2.09
|
|
4
|
Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.
|
Clin Cancer Res
|
2010
|
1.92
|
|
5
|
Language matters: "sometimes we withdraw treatment but we never withdraw care".
|
J Palliat Med
|
2007
|
1.45
|
|
6
|
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
|
J Clin Oncol
|
2009
|
1.24
|
|
7
|
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan.
|
Neurosurgery
|
2011
|
1.14
|
|
8
|
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
|
Cancer
|
2008
|
1.13
|
|
9
|
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
|
Oncogene
|
2003
|
1.06
|
|
10
|
Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships.
|
J Med Chem
|
2011
|
1.03
|
|
11
|
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
|
Cancer Res
|
2003
|
1.00
|
|
12
|
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
|
Pituitary
|
2011
|
0.98
|
|
13
|
A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models.
|
Biochem Pharmacol
|
2002
|
0.92
|
|
14
|
Head and neck squamous cell carcinoma in FAMMM syndrome.
|
Head Neck
|
2009
|
0.91
|
|
15
|
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas.
|
Proc Natl Acad Sci U S A
|
2007
|
0.91
|
|
16
|
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
|
J Gastrointest Surg
|
2007
|
0.91
|
|
17
|
NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
|
Biochemistry
|
2004
|
0.90
|
|
18
|
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
|
Pancreas
|
2008
|
0.89
|
|
19
|
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
|
Mol Cancer Ther
|
2005
|
0.89
|
|
20
|
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue.
|
J Neurooncol
|
2007
|
0.89
|
|
21
|
The intensity and frequency of moral distress among different healthcare disciplines.
|
J Clin Ethics
|
2013
|
0.89
|
|
22
|
Cost savings from palliative care teams and guidance for a financially viable palliative care program.
|
Health Serv Res
|
2014
|
0.88
|
|
23
|
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide.
|
Mol Cancer Ther
|
2006
|
0.86
|
|
24
|
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance.
|
J Biol Chem
|
2007
|
0.85
|
|
25
|
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
|
Int J Cancer
|
2006
|
0.85
|
|
26
|
Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide.
|
Biochem Biophys Res Commun
|
2002
|
0.85
|
|
27
|
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
|
Neurosurgery
|
2014
|
0.84
|
|
28
|
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.
|
J Neurooncol
|
2006
|
0.84
|
|
29
|
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
|
Clin Cancer Res
|
2002
|
0.84
|
|
30
|
Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study.
|
Neurosurgery
|
2011
|
0.83
|
|
31
|
Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells.
|
Int J Cancer
|
2005
|
0.83
|
|
32
|
The use of fluorescent probes in the study of reactive oxygen species in pancreatic cancer cells.
|
Methods Mol Biol
|
2013
|
0.80
|
|
33
|
The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis.
|
Adv Drug Deliv Rev
|
2005
|
0.80
|
|
34
|
Treatment preferences of seriously ill patients.
|
N Engl J Med
|
2002
|
0.80
|
|
35
|
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
|
Cancer
|
2014
|
0.80
|
|
36
|
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
|
Surg Oncol Clin N Am
|
2004
|
0.79
|
|
37
|
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.
|
Mol Cancer Ther
|
2013
|
0.79
|
|
38
|
The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green.
|
J Neurooncol
|
2011
|
0.79
|
|
39
|
Stereotactic radiosurgery plays a critical role in enhancing long-term survival in a patient with pancreatic cancer metastatic to the brain.
|
Anticancer Res
|
2013
|
0.78
|
|
40
|
Computational protein chemistry of p53 and p53 peptides.
|
Front Biosci
|
2004
|
0.77
|
|
41
|
Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice.
|
Surg Innov
|
2005
|
0.77
|
|
42
|
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
|
Oncology
|
2012
|
0.77
|
|
43
|
Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice.
|
Surg Innov
|
2006
|
0.76
|
|
44
|
Is it always wrong to perform futile CPR?
|
N Engl J Med
|
2010
|
0.75
|
|
45
|
Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer.
|
Lancet Oncol
|
2005
|
0.75
|
|
46
|
Acute ascending aortic dissection diagnosed with transthoracic echocardiography.
|
J Am Soc Echocardiogr
|
2009
|
0.75
|
|
47
|
Tackling medical futility in Texas.
|
N Engl J Med
|
2007
|
0.75
|
|
48
|
BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo.
|
Int J Oncol
|
2005
|
0.75
|